Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory disease... Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Show more
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., Dec. 10, 2024 THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its...
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PR...
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA PR Newswire THOUSAND OAKS, Calif., Dec. 5, 2024 Investment Establishes Second Facility in Holly Springs; Builds on Previous...
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Dec. 2, 2024 THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present...
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE PR Newswire THOUSAND OAKS, Calif., Nov. 29, 2024 THOUSAND OAKS, Calif., Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY PR Newswire THOUSAND OAKS, Calif., Nov. 26, 2024 MariTide Demonstrated...
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM PR Newswire THOUSAND OAKS, Calif., Nov. 26, 2024 THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/...
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT PR Newswire THOUSAND OAKS, Calif., Nov. 20, 2024 Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.02 | -0.768060836502 | 263 | 264.73 | 258.5 | 2071423 | 261.87651835 | CS |
| 4 | -16.02 | -5.78339350181 | 277 | 281.3799 | 253.3 | 3902823 | 268.50498271 | CS |
| 12 | -58.02 | -18.1880877743 | 319 | 329.17 | 253.3 | 3273929 | 287.36829438 | CS |
| 26 | -52.36 | -16.7102827599 | 313.34 | 346.85 | 253.3 | 2536840 | 303.38167592 | CS |
| 52 | -27.32 | -9.47624002775 | 288.3 | 346.85 | 253.3 | 2659288 | 298.41146723 | CS |
| 156 | 34.72 | 15.3451781137 | 226.26 | 346.85 | 211.73 | 2703021 | 264.31018173 | CS |
| 260 | 20.7 | 8.6149492259 | 240.28 | 346.85 | 177.05 | 2696523 | 250.37086096 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
